2013
DOI: 10.1038/nm.3283
|View full text |Cite
|
Sign up to set email alerts
|

Huntington's disease: easing the NMDAR traffic jam

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2015
2015
2017
2017

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 12 publications
0
2
0
Order By: Relevance
“…Administration of ephrin-B2 counteracts this loss of extrasynaptic and synaptic NMDAR both in vitro and in vivo in the NMDAR-antibody transfer mouse model ( Mikasova et al , 2012 ; Planagumà et al , 2016 ). Notably, aberrant NMDAR trafficking is also pivotal in the pathophysiology of Huntington’s disease ( Daggett and Yang, 2013 ), and reagents that regulate human ephrin-like receptors are under investigation for treatment of Huntington’s disease ( Ramakrishnan, 2003 ). Clinical practice offers another paradigm of a similar treatment approach in genetic and autoimmune neurology where 4-aminopyridine has proved beneficial in two disorders affecting P/Q type voltage-dependent calcium channels: episodic ataxia type 2 due to P/Q calcium channel gene mutations and Lambert-Eaton syndrome due to P/Q calcium channel autoantibodies ( Strupp et al , 2011 ).…”
Section: Conclusion and Future Directivesmentioning
confidence: 99%
“…Administration of ephrin-B2 counteracts this loss of extrasynaptic and synaptic NMDAR both in vitro and in vivo in the NMDAR-antibody transfer mouse model ( Mikasova et al , 2012 ; Planagumà et al , 2016 ). Notably, aberrant NMDAR trafficking is also pivotal in the pathophysiology of Huntington’s disease ( Daggett and Yang, 2013 ), and reagents that regulate human ephrin-like receptors are under investigation for treatment of Huntington’s disease ( Ramakrishnan, 2003 ). Clinical practice offers another paradigm of a similar treatment approach in genetic and autoimmune neurology where 4-aminopyridine has proved beneficial in two disorders affecting P/Q type voltage-dependent calcium channels: episodic ataxia type 2 due to P/Q calcium channel gene mutations and Lambert-Eaton syndrome due to P/Q calcium channel autoantibodies ( Strupp et al , 2011 ).…”
Section: Conclusion and Future Directivesmentioning
confidence: 99%
“…Furthermore, previous studies have indicated that NMDA receptors were involved in the pathological mechanisms of Parkinson, Alzheimer and Huntington diseases (Xu et al . ; Daggett & Yang ; Hanson et al . ).…”
Section: Discussionmentioning
confidence: 99%